SCHEMBL735160

SCHEMBL735160

CCOC(=O)Cc1[nH]c2ccccc2c1CC(=O)C(=O)OCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.54
LMNA P02545 3/20 0.54
PKM P14618 1/20 0.50
HTR6 P50406 2/20 0.46
ALDH1A1 P00352 8/20 0.46
HSD17B10 Q99714 4/20 0.46
MAPT P10636 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HCRTR1 O43613 1/20 0.46
RAB9A P51151 1/20 0.46
GAA P10253 2/20 0.46
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
HTR1A P08908 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19193162 0.82 KDM4E (0.60) KDM4ELMNAPKMHTR6ALDH1A1
SCHEMBL28819201 0.81 KDM4E (0.58) KDM4ELMNAPKMHTR6ALDH1A1
SCHEMBL728638 0.81 KDM4E (0.55) KDM4ELMNAPKMALDH1A1HSD17B10
SCHEMBL11084373 0.80 HTR6 (0.62) KDM4ELMNAPKMHTR6ALDH1A1
SCHEMBL11625839 0.80 KDM4E (0.57) KDM4ELMNAPKMHTR6ALDH1A1
SCHEMBL1165573 0.78 KDM4E (0.68) KDM4ELMNAPKMHTR6ALDH1A1
SCHEMBL31487317 0.78 KDM4E (0.68) KDM4ELMNAPKMHTR6ALDH1A1
SCHEMBL11866647 0.78 HTR6 (0.63) KDM4ELMNAPKMHTR6ALDH1A1
SCHEMBL16669624 0.77 KDM4E (0.57) KDM4ELMNAPKMALDH1A1HSD17B10
SCHEMBL5198795 0.77 KDM4E (0.64) KDM4ELMNAPKMHTR6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138173-B2 Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-03-20 US disclosed
US-8138173-B2 Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-03-20 US disclosed
US-20090069299-A1 Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-12 US disclosed
US-20090069299-A1 Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069299-A1 Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods IL4, IL2, IL5 KDM4E 3301/4885LMNA 2914/4885PKM 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.